GlassScriptPhysician profile
Gerard Fumo
NPI 1770524753
$2,326.91
in general payments reported to CMS, 2019-2025
40 companies · $497 in 2025
The $497 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $182 · 2021: $11.92 · 2022: $14.60 · 2023: $203 · 2024: $77.77 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $364.47 | 2019-2025 | Reblozyl, Pomalyst, Abecma |
| Pfizer INC. | $185.12 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $147.41 | 2019-2025 | Opdivo |
| Genentech USA, INC. | $132.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $117.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $109.03 | 2019-2025 | Tagrisso |
| Merck Sharp & Dohme LLC | $95.06 | 2019-2023 | Keytruda |
| Astellas Pharma US INC | $86.02 | 2019-2025 | Padcev |
| Coherus Oncology, INC. | $84.61 | 2024-2025 | Loqtorzi |
| Bayer Healthcare Pharmaceuticals INC. | $82.15 | 2019-2020 | |
| Genzyme Corporation | $81.97 | 2019 | |
| Glaxosmithkline, LLC. | $66.28 | 2025 | Ojjaara, Blenrep, Zejula |
| Ipsen Biopharmaceuticals, INC | $59.17 | 2019-2020 | |
| Incyte Corporation | $57.33 | 2019-2024 | Jakafi |
| Janssen Biotech, INC. | $57.18 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $50.98 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $39.64 | 2019 | |
| Jazz Pharmaceuticals INC. | $36.45 | 2019 | |
| Seagen INC. | $36.14 | 2019 | |
| Amgen INC. | $35.41 | 2019 | |
| Exelixis INC. | $34.95 | 2019 | |
| Taiho Oncology, INC. | $33.73 | 2019 | |
| Genmab U.S., INC. | $31.17 | 2025 | Tivdak |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.86 | 2019 | |
| Dova Pharmaceuticals | $29.17 | 2019-2020 | |
| Advanced Accelerator Applications | $24.84 | 2020 | |
| Eisai INC. | $20.68 | 2019 | |
| Array Biopharma INC | $20.61 | 2025 | Mektovi, Tukysa, Braftovi |
| Mylan Institutional INC. | $19.95 | 2020 | |
| Kyowa Kirin, INC. | $18.86 | 2019 | |
| Mirati Therapeutics, INC. | $17.88 | 2023 | Krazati |
| Rigel Pharmaceuticals, INC. | $17.67 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.35 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.12 | 2019 | |
| Lilly USA, LLC | $15.06 | 2019 | |
| Aurobindo Pharma USA, INC. | $14.22 | 2019 | |
| Emd Serono, INC. | $13.38 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Fumo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.